Skip to main
XTNT

XTNT Stock Forecast & Price Target

XTNT Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Xtant Medical Holdings is well-positioned for growth and profitability in the coming years, with a diverse portfolio of orthobiologics and spinal implant products and a strong focus on the U.S. market. The recent acquisition of Dilon Technologies' HEMOBLAST Bellows product and US sales force, along with the finalization of the sale of Coflex, CoFix, and OUS business, are expected to contribute to Xtant's growth and improved financials. Despite some legacy performance challenges and the need for additional capital, the company's solid financial position and expected top-line acceleration in Orthobiologics make it a strong buy at its current valuation.

Bears say

Xtant Medical Holdings is facing various risks, including competition, legacy performance, and the need for additional capital, as well as a softer-than-expected procedure environment. The company's current capital position is also a concern, as it ended 4Q25 with only $17.3 million in cash and may require additional capital to fund operations. Additionally, with the company's expected decline in spinal implant sales and lower gross margins for FY26, it currently trades at a 1.0x discount to its peers, and we believe there is further downside potential for the stock.

XTNT has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Xtant Medical Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Xtant Medical Holdings (XTNT) Forecast

Analysts have given XTNT a Strong Buy based on their latest research and market trends.

According to 1 analysts, XTNT has a Strong Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Xtant Medical Holdings (XTNT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.